Asthma gene clue: why some kids respond better to inhalers

NCT ID NCT03592212

First seen May 13, 2026 · Last updated Jun 23, 2026 · Updated 7 times

Summary

This study looked at whether a variation in the PDE4 gene influences how well children with persistent asthma respond to the common inhaler drug salbutamol. Researchers measured lung function before and after giving salbutamol to 99 children aged 6 to 18. The goal was to see if the gene variant could explain differences in drug response, which might one day help personalize asthma treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hôpital Necker -Enfants Malades

    Paris, 75015, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Salbutamol

What this could lead to

If successful, this could help doctors predict which children with asthma will respond best to salbutamol, leading to more personalized treatment.

What could go wrong

This was a small, terminated study (99 participants) that only looked at a genetic link, not a treatment. The results may not apply to all children or change current care.

Conditions

The condition(s) this trial relates to.

asthma childhood onset asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.